--- title: Bio-Techne (TECH) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/tech ticker: TECH as_of: 2026-10-17 sector: Healthcare industry: Biotechnology --- # Bio-Techne (TECH) Bio-Techne (TECH) closed at $72.57 on Oct 16, 2026, overvalued by 150% vs its model value of $29.05 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $72.57 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $29.05 | | Price vs model | overvalued by 150% vs model | | Range of that model | $21.05 – $49.14 | | Market value | $11.4B | | P/E (fiscal 2026) | 62.6 | | Net margin (fiscal 2026) | 15.0% | | Free cash flow (fiscal 2026) | $263.2M | | Dividend yield (trailing twelve months) | 0.44% | | Beta | 1.29 | | Cost of capital (WACC) | 9.94% | | Business classification | Mature & Stable (Low/slowing growth (~2% recent), Moderate margins (15% net margin), Highly cyclical earnings) | ## On the stock lists | List | Place | Figure | Page | | --- | ---: | ---: | --- | | Near 52-week highs | #25 | −0.1% | https://sweetvaluelab.com/lists/near-52-week-highs | ## Dividends | Figure | Value | | --- | ---: | | Trailing dividend yield | 0.44% | | Dividends per share, last 12 months | $0.32 | | Dividends / free cash flow (fiscal 2026) | 19.0% | | Raised | — | | Growth over 5 years | 0.0% a year | | Latest payment | $0.08, ex-date Aug 24, 2026, paid Sep 4, 2026 | | Year of payments | Dividends per share | | --- | ---: | | To Aug 13, 2021 | $0.32 | | To Aug 12, 2022 | $0.32 | | To Aug 17, 2023 | $0.32 | | To Aug 19, 2024 | $0.32 | | To Aug 18, 2025 | $0.32 | | Trailing twelve months (to Aug 24, 2026) | $0.32 | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $29.05 | $21.05 | $49.14 | | DCF · Perpetuity growth · 10y | cross check | $33.83 | $24.71 | $56.40 | | DCF · EBITDA exit · 5y | cross check | $59.86 | $47.43 | $74.37 | | DCF · EBITDA exit · 10y | cross check | $61.15 | $46.10 | $80.79 | | P/E · peers | cross check | $45.54 | $40.82 | $54.63 | | P/E · own history | cross check | $99.49 | $74.21 | $182.51 | | PEG | sanity check | $50.82 | $50.82 | $50.82 | | EV/EBITDA · peers | cross check | $57.10 | $43.92 | $63.41 | | EV/Revenue · peers | cross check | $50.87 | $40.05 | $56.15 | | Earnings power value | cross check | $12.92 | $11.28 | $15.14 | | Dividend discount | cross check | $5.02 | $3.59 | $7.66 | ## Insider activity (SEC Form 4) No open-market insider buys or sales filed in the past 90 days. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 28, 2026 | HIGGINS JOHN L | Director | Option/RSU exercise | 15,940 | $0 | | Sep 28, 2026 | HIGGINS JOHN L | Director | Tax withholding | 5,562 | $403,300.6 | | Sep 28, 2026 | HIGGINS JOHN L | Director | Option/RSU exercise | 15,940 | $0 | | Sep 22, 2026 | BAUMGARTNER ROBERT V | Director | Option/RSU exercise | 15,940 | $0 | | Sep 22, 2026 | BAUMGARTNER ROBERT V | Director | Tax withholding | 5,559 | $403,305.5 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Sep 23, 2026 | 8-K | 5.07 Submission of Matters to a Shareholder Vote; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/842023/000114036126037450/ef20082601_8k.htm | | Sep 14, 2026 | DEFA14A | Additional proxy materials | https://www.sec.gov/Archives/edgar/data/842023/000114036126036500/ef20081960_defa14a.htm | | Sep 14, 2026 | 8-K | 8.01 Other Events | https://www.sec.gov/Archives/edgar/data/842023/000114036126036499/ef20081960_8k.htm | | Sep 9, 2026 | DEFA14A | Additional proxy materials | https://www.sec.gov/Archives/edgar/data/842023/000114036126036072/ef20081813_defa14a.htm | | Sep 2, 2026 | DEFA14A | Additional proxy materials | https://www.sec.gov/Archives/edgar/data/842023/000114036126035490/ef20081553_defa14a.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Ruane Cunniff | 2026-06-30 | 3,348,841 | $236.6M | | Mairs & Power | 2026-06-30 | 2,700,698 | $190.8M | | Lee Ainslie | 2026-06-30 | 1,535,610 | $108.5M | | Wallace Weitz | 2026-06-30 | 543,200 | $38.4M | 7 tracked managers in all. ## About Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufact… --- Source: https://sweetvaluelab.com/stocks/tech (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.